{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:56:39Z","timestamp":1789239399601,"version":"build-2803163510"},"reference-count":61,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:00:00Z","timestamp":1724371200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Commission of Health and Family Planning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.apsb.2024.08.019","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T12:49:43Z","timestamp":1724849383000},"page":"5235-5248","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Identification of USP2 as a novel target to induce degradation of KRAS in myeloma cells"],"prefix":"10.1016","volume":"14","author":[{"given":"Yingying","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunzhao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjie","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chujiao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3288-5205","authenticated-orcid":false,"given":"Hu","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanzhang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leimiao","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ligen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiwu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyue","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiliang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3063-8473","authenticated-orcid":false,"given":"Zhijian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7909-8757","authenticated-orcid":false,"given":"Yingli","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2024.08.019_bib1","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrc3106","article-title":"RAS oncogenes: weaving a tumorigenic web","volume":"11","author":"Pylayeva-Gupta","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.apsb.2024.08.019_bib2","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1182\/blood.2020010572","article-title":"Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity","volume":"138","author":"Sacco","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2024.08.019_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2008.06.020","article-title":"SnapShot: ras signaling","volume":"133","author":"Cully","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2024.08.019_bib4","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nm0813-949","article-title":"US National Cancer Institute's new Ras project targets an old foe","volume":"19","author":"Thompson","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2024.08.019_bib5","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2024.08.019_bib6","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.apsb.2022.10.023","article-title":"Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancer","volume":"13","author":"Feng","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2024.08.019_bib7","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nrd4389","article-title":"Drugging the undruggable RAS: mission possible?.","volume":"13","author":"Cox","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2024.08.019_bib8","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nature09837","article-title":"Initial genome sequencing and analysis of multiple myeloma","volume":"471","author":"Chapman","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2024.08.019_bib9","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.apsb.2019.03.002","article-title":"Targeting the untargetable KRAS in cancer therapy","volume":"9","author":"Liu","year":"2019","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2024.08.019_bib10","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1038\/s41467-021-22125-z","article-title":"The origins and genetic interactions of KRAS mutations are allele- and tissue-specific","volume":"12","author":"Cook","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2024.08.019_bib11","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1038\/leu.2008.142","article-title":"Clinical and biological significance of RAS mutations in multiple myeloma","volume":"22","author":"Chng","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.apsb.2024.08.019_bib12","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3390\/cancers12020455","article-title":"Exon-4 mutations in KRAS affect MEK\/ERK and PI3K\/AKT signaling in human multiple myeloma cell lines","volume":"12","author":"Wei\u00dfbach","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.apsb.2024.08.019_bib13","doi-asserted-by":"crossref","first-page":"20004","DOI":"10.1073\/pnas.2005052117","article-title":"Activating KRAS, NRAS, and BRAF mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma","volume":"117","author":"Shirazi","year":"2020","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.apsb.2024.08.019_bib14","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.chembiol.2019.12.006","article-title":"Exploring targeted degradation strategy for oncogenic KRAS(G12C)","volume":"27","author":"Zeng","year":"2020","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.apsb.2024.08.019_bib15","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41586-021-04065-2","article-title":"Diverse alterations associated with resistance to KRAS(G12C) inhibition","volume":"599","author":"Zhao","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2024.08.019_bib16","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRAS(G12C) inhibition in cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2024.08.019_bib17","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1016\/j.apsb.2022.02.022","article-title":"Non-small molecule PROTACs (NSM-PROTACs): protein degradation kaleidoscope","volume":"12","author":"Ma","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2024.08.019_bib18","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1021\/acs.jmedchem.1c01774","article-title":"Discovery of the first-in-class agonist-based SOS1 PROTACs effective in human cancer cells harboring various KRAS mutations","volume":"65","author":"Zhou","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.08.019_bib19","doi-asserted-by":"crossref","first-page":"288","DOI":"10.15252\/emmm.201505972","article-title":"OTUB1 triggers lung cancer development by inhibiting RAS monoubiquitination","volume":"8","author":"Baietti","year":"2016","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.apsb.2024.08.019_bib20","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1021\/acscentsci.0c00411","article-title":"Targeted degradation of oncogenic KRAS(G12C) by VHL-recruiting PROTACs","volume":"6","author":"Bond","year":"2020","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.apsb.2024.08.019_bib21","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.1016\/j.apsb.2023.07.019","article-title":"Function, mechanism and drug discovery of ubiquitin and ubiquitin-like modification with multiomics profiling for cancer therapy","volume":"13","author":"Jiang","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2024.08.019_bib22","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1016\/j.apsb.2023.06.016","article-title":"The role of E3 ubiquitin ligases in bone homeostasis and related diseases","volume":"13","author":"Dong","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2024.08.019_bib23","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1126\/science.aap8210","article-title":"LZTR1 is a regulator of RAS ubiquitination and signaling","volume":"362","author":"Bigenzahn","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.apsb.2024.08.019_bib24","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41418-019-0395-5","article-title":"LZTR1 facilitates polyubiquitination and degradation of RAS-GTPases","volume":"27","author":"Abe","year":"2020","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.apsb.2024.08.019_bib25","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1038\/s41418-019-0309-6","article-title":"MEK nuclear localization promotes YAP stability via sequestering \u03b2-TrCP in KRAS mutant cancer cells","volume":"26","author":"Xu","year":"2019","journal-title":"Cel Death Differ"},{"key":"10.1016\/j.apsb.2024.08.019_bib26","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1158\/1541-7786.MCR-16-0369","article-title":"Deubiquitinase USP18 loss mislocalizes and destabilizes KRAS in lung cancer","volume":"15","author":"Mustachio","year":"2017","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.apsb.2024.08.019_bib27","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.chembiol.2017.03.002","article-title":"Lithocholic acid hydroxyamide destabilizes Cyclin D1 and induces G0\/G1 arrest by inhibiting deubiquitinase USP2a","volume":"24","author":"Magiera","year":"2017","journal-title":"Cel Chem Biol"},{"key":"10.1016\/j.apsb.2024.08.019_bib28","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1038\/s41388-022-02275-0","article-title":"Loss of deubiquitylase USP2 triggers development of glioblastoma via TGF-\u03b2 signaling","volume":"41","author":"Tu","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.apsb.2024.08.019_bib29","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s13238-012-2120-8","article-title":"USP2a positively regulates TCR-induced NF-\u03baB activation by bridging MALT1-TRAF6","volume":"4","author":"Li","year":"2013","journal-title":"Protein Cell"},{"key":"10.1016\/j.apsb.2024.08.019_bib30","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1161\/CIRCRESAHA.115.307298","article-title":"The deubiquitylase USP2 regulates the LDLR pathway by counteracting the E3-ubiquitin ligase IDOL","volume":"118","author":"Nelson","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.apsb.2024.08.019_bib31","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jocn.2012.03.050","article-title":"Up-regulation of USP2a and FASN in gliomas correlates strongly with glioma grade","volume":"20","author":"Tao","year":"2013","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.apsb.2024.08.019_bib32","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.3390\/ijms22031209","article-title":"USP2-related cellular signaling and consequent pathophysiological outcomes","volume":"22","author":"Kitamura","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2024.08.019_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145155","article-title":"USP2-45 is a circadian clock output effector regulating calcium absorption at the post-translational level","volume":"11","author":"Pouly","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2024.08.019_bib34","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1177\/0748730414544741","article-title":"USP2 regulates the intracellular localization of PER1 and circadian gene expression","volume":"29","author":"Yang","year":"2014","journal-title":"J Biol Rhythms"},{"key":"10.1016\/j.apsb.2024.08.019_bib35","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.7150\/ijbs.21637","article-title":"The molecular mechanisms of regulation on USP2's alternative splicing and the significance of its products","volume":"13","author":"Zhu","year":"2017","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.apsb.2024.08.019_bib36","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1038\/s41467-023-37617-3","article-title":"Targeting USP2 regulation of VPRBP-mediated degradation of p53 and PD-L1 for cancer therapy","volume":"14","author":"Yi","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2024.08.019_bib37","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1038\/s41418-020-0538-8","article-title":"The deubiquitylase USP2 maintains ErbB2 abundance via counteracting endocytic degradation and represents a therapeutic target in ErbB2-positive breast cancer","volume":"27","author":"Zhang","year":"2020","journal-title":"Cel Death Differ"},{"key":"10.1016\/j.apsb.2024.08.019_bib38","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/nsb1203-980","article-title":"Announcing the worldwide protein data bank","volume":"10","author":"Berman","year":"2003","journal-title":"Nat Struct Biol"},{"key":"10.1016\/j.apsb.2024.08.019_bib39","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/prot.24350","article-title":"Motional timescale predictions by molecular dynamics simulations: case study using proline and hydroxyproline sidechain dynamics","volume":"82","author":"Aliev","year":"2014","journal-title":"Proteins"},{"key":"10.1016\/j.apsb.2024.08.019_bib40","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/jcc.20035","article-title":"Development and testing of a general amber force field","volume":"25","author":"Wang","year":"2004","journal-title":"J Comput Chem"},{"key":"10.1016\/j.apsb.2024.08.019_bib41","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1021\/ct700200b","article-title":"P-LINCS: a parallel linear constraint solver for molecular simulation","volume":"4","author":"Hess","year":"2008","journal-title":"J Chem Theor Comput"},{"key":"10.1016\/j.apsb.2024.08.019_bib42","doi-asserted-by":"crossref","DOI":"10.1063\/5.0044166","article-title":"Analytical hessians for Ewald and particle mesh Ewald electrostatics","volume":"154","author":"Simmonett","year":"2021","journal-title":"J Chem Phys"},{"key":"10.1016\/j.apsb.2024.08.019_bib43","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/s41592-019-0506-8","article-title":"Promoting transparency and reproducibility in enhanced molecular simulations","volume":"16","year":"2019","journal-title":"Nat Methods"},{"key":"10.1016\/j.apsb.2024.08.019_bib44","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1021\/ci300604z","article-title":"Lessons learned in empirical scoring with smina from the CSAR 2011 benchmarking exercise","volume":"53","author":"Koes","year":"2013","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.apsb.2024.08.019_bib45","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nchembio.935","article-title":"Adenanthin targets peroxiredoxin I and II to induce differentiation of leukemic cells","volume":"8","author":"Liu","year":"2012","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.apsb.2024.08.019_bib46","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1021\/acs.jcim.3c00556","article-title":"Discovery of novel SIRT1\/2 inhibitors with effective cytotoxicity against human leukemia cells","volume":"63","author":"Cai","year":"2023","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.apsb.2024.08.019_bib47","doi-asserted-by":"crossref","first-page":"E4801","DOI":"10.1073\/pnas.1606655113","article-title":"Gambogic acid identifies an isoform-specific druggable pocket in the middle domain of Hsp90\u03b2","volume":"113","author":"Yim","year":"2016","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.apsb.2024.08.019_bib48","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2174\/1568009619666191202101330","article-title":"Old and new approaches to target the Hsp90 chaperone","volume":"20","author":"Sanchez","year":"2020","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.apsb.2024.08.019_bib49","doi-asserted-by":"crossref","first-page":"4763","DOI":"10.1038\/ncomms5763","article-title":"Screening of DUB activity and specificity by MALDI-TOF mass spectrometry","volume":"5","author":"Ritorto","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2024.08.019_bib50","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.3390\/ijms22094546","article-title":"Advances in the development ubiquitin-specific peptidase (USP) Inhibitors","volume":"22","author":"Chen","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2024.08.019_bib51","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.7150\/ijbs.70960","article-title":"IKZF1 selectively\u00a0enhances homologous recombination repair by interacting with CtIP and USP7 in multiple myeloma","volume":"18","author":"Liu","year":"2022","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.apsb.2024.08.019_bib52","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1182\/blood-2014-10-605584","article-title":"Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies","volume":"125","author":"Peterson","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2024.08.019_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0183-1","article-title":"USP15 inhibits multiple myeloma cell apoptosis through activating a feedback loop with the transcription factor NF-\u03baBp65","volume":"50","author":"Zhou","year":"2018","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.apsb.2024.08.019_bib54","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/s41388-021-02167-9","article-title":"Deubiquitylase USP12 induces pro-survival autophagy and bortezomib resistance in multiple myeloma by stabilizing HMGB1","volume":"41","author":"Li","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.apsb.2024.08.019_bib55","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1038\/s41401-023-01083-w","article-title":"Inhibition of USP10 induces myeloma cell apoptosis by promoting cyclin D3 degradation","volume":"44","author":"Xu","year":"2023","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.apsb.2024.08.019_bib56","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1021\/np300118c","article-title":"Gambogic acid deactivates cytosolic and mitochondrial thioredoxins by covalent binding to the functional domain","volume":"75","author":"Yang","year":"2012","journal-title":"J Nat Prod"},{"key":"10.1016\/j.apsb.2024.08.019_bib57","first-page":"1299","article-title":"Inhibition of NF-kappaB and Akt pathways by an antibody-avidin fusion protein sensitizes malignant B-cells to cisplatin-induced apoptosis","volume":"36","author":"Suzuki","year":"2010","journal-title":"Int J Oncol"},{"key":"10.1016\/j.apsb.2024.08.019_bib58","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/cas.12458","article-title":"Gambogic acid suppresses hypoxia-induced hypoxia-inducible factor-1\u03b1\/vascular endothelial growth factor expression via inhibiting phosphatidylinositol 3-kinase\/Akt\/mammalian target protein of rapamycin pathway in multiple myeloma cells","volume":"105","author":"Wang","year":"2014","journal-title":"Cancer Sci"},{"key":"10.1016\/j.apsb.2024.08.019_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115124","article-title":"Annual review\u00a0of KRAS inhibitors in 2022","volume":"249","author":"Wang","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2024.08.019_bib60","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41392-023-01441-4","article-title":"Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS","volume":"8","author":"Yin","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.apsb.2024.08.019_bib61","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1038\/s41598-018-21476-w","article-title":"6-Thioguanine is a noncompetitive and slow binding inhibitor of human deubiquitinating protease USP2","volume":"8","author":"Chuang","year":"2018","journal-title":"Sci Rep"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383524003381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383524003381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T23:15:55Z","timestamp":1734390955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383524003381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":61,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2211383524003381"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2024.08.019","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of USP2 as a novel target to induce degradation of KRAS in myeloma cells","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2024.08.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}